DAVID RAMOS: Open Payments
NPI 1114227436 · RIVERSIDE, RI. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,251 in 148 payments from 22 companies in 2025. Trend: 2023 $2,684 · 2024 $3,217 · 2025 $3,251
Food & beverage: $3,251
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 35 | $689 |
| Novo Nordisk Inc | 18 | $383 |
| AstraZeneca Pharmaceuticals LP | 13 | $375 |
| PFIZER INC. | 15 | $333 |
| Lilly USA, LLC | 11 | $276 |
| Abbott Laboratories | 11 | $213 |
| Sumitomo Pharma America, Inc. | 6 | $128 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 5 | $118 |
| Ardelyx, Inc. | 4 | $107 |
| GlaxoSmithKline, LLC. | 5 | $98 |
Products named: AIRSUPRA, JARDIANCE, VRAYLAR, FREESTYLE LIBRE 3, Wegovy, QULIPTA, UBRELVY, Rybelsus.
Industry payments across RI — which companies pay providers there.
